The expansion of the Lambda variant of Coronavirus, C.37 – otherwise known as the ‘Peruvian variant’ – has the scientific and health communities worried about the speed at which it is growing among infected patients. The World Health Organization has called it “concerning”.

Initial findings suggest that the variant is more transmissible than others. However, scientists say that it is difficult to know this with any certainty because of the lack of reliable data. As we pointed out on 4 July, Lambda is spreading fast within Peru and neighbouring countries. However, it is unclear whether this is the consequence of the intrinsic nature of the variant or the overcrowded conditions and porous frontiers that characterise South American countries.

According to Pablo Tsukayama from the Cayetano Heredia University in Lima, quoted in an article last week in El País, problems of evaluation of the variant abound, not least because each South American country has its own methodology for analysing the pandemic. In Peru, he says, funds were only available for the study of the Lambda variant as of the end of April 2021. The authorities, he claims, have been resistant to handing over the data collected by the health ministry.

According to Tsukayama, the only solid evidence for the danger of Lambda is the speed at which it appears to have spread in Peru, for which it is still unclear whether this is attributable to the virus itself or the social context in which it multiplies. “We have not done these calculations yet”, he says “in part because we have not collected sufficient sequences. We are in the process [of doing so]”. He says that the lack of public health resources makes this more difficult in countries like Peru than in those like the United Kingdom.

Another problem is identifying whether Lambda is more resistant to the vaccines being administered in Peru and its neighbours. Preliminary evidence from Chile suggests it is.

Peru remains one of the countries worst affected by Covid-19 according to adjusted figures published since the end of May. It seems likely that this month the official death toll will surpass 200,000. The number of registered cases already exceeds 2 million (out of a total population of roughly 31 million). Its vaccination programme has only reached a small proportion of the population and there have been egregious inequalities in its distribution, with the capital receiving many more doses per capita than elsewhere.